[Movember health care initiative 2019: prostate cancer screening at the University Hospital Frankfurt].

Background Men die earlier than women in Germany. Men also have impaired access to cancer screening compared to women. Objectives Our Movember campaign 2019 at University Hospital Frankfurt (UKF) aimed at improving health care awareness in the context of prostate cancer checkup. Materials and methods In November 2019, every male employee of the UKF with a minimum age of 45 yrs (or 40 yrs with a first degree relative with prostate cancer) was offered a free prostate cancer checkup. This checkup contained digital rectal examination (DRE), transrectal ultrasound and PSA (prostata-specific antigen) testing. Results Overall, 121/840 employees (14.4%) participated in the Movember campaign. A first degree relative with prostate cancer was reported in overall by 14% of the participants (n=17). At least one prior prostate cancer check up had 33%. A total of 2.5% (n=3) had one prior negative prostate biopsy. Median age was 54 yrs (interquartile range 50-58). Median PSA level was 0.9ng/ml and median free-PSA 0.3ng/ml. A suspicious DRE was found in 5% (n=6). After stratification according to age (<= 50 yrs vs. >50 yrs), participants over 50 yrs had a significantly higher PSA level (1.0ng/ml vs. 0.7ng/ml,p<0.01) and had more frequently at least one prior prostate cancer checkup in the past (42.0 vs. 12.1%,p<0.01). All suspicious DREs were in the cohort >50 yrs. Overall, 32.2% (n=39) had at least a suspicious checkup. A total of 3.3% (n=4) had suspicious PSA levels. 17.4% (n=21) of the participants had a suspicious PSA ratio (<20%) only. During follow-up, 6 prostate biopsies were performed, with the detection of one case of intermediate-risk prostate cancer (Gleason 3+4, pT3a, pPn1, pNx, R0). Conclusion Overall, 121 employees participated in our Movember Prostate cancer checkup campaign with measurement of the PSA level. Suspicious results were recorded in 32.2%. One employee was diagnosed and successfully treated with an intermediate-risk prostate cancer.